48,830
edits
(more) |
m (→IHC: more) |
||
Line 18: | Line 18: | ||
*AE1/AE3 (pankeratin). | *AE1/AE3 (pankeratin). | ||
===Big | ===Big panels=== | ||
A MSH panel | ====A MSH MFH panel==== | ||
*CD34 - [[GIST]], [[angiosarcoma]], [[solitary fibrous tumour]]/[[hemangiopericytoma]], [[Kaposi sarcoma]], [[DFSP]]. | *CD34 - [[GIST]], [[angiosarcoma]], [[solitary fibrous tumour]]/[[hemangiopericytoma]], [[Kaposi sarcoma]], [[DFSP]]. | ||
*S100 - neural marker, sensitive for [[malignant melanoma]], Langerhans cells, [[clear cell sarcoma]]. | *S100 - neural marker, sensitive for [[malignant melanoma]], Langerhans cells, [[clear cell sarcoma]]. | ||
Line 36: | Line 36: | ||
*Beta-catenin - a small subset of soft tissue lesions: | *Beta-catenin - a small subset of soft tissue lesions: | ||
**Desmoidtype [[fibromatosis]] (~70%), solitary fibrous tumour & endometrial stromal sarcoma (~40%), synovial sarcoma (~30%).<ref name=pmid15375433>{{cite journal |author=Ng TL, Gown AM, Barry TS, ''et al.'' |title=Nuclear beta-catenin in mesenchymal tumors |journal=Mod. Pathol. |volume=18 |issue=1 |pages=68–74 |year=2005 |month=January |pmid=15375433 |doi=10.1038/modpathol.3800272 |url=}}</ref> | **Desmoidtype [[fibromatosis]] (~70%), solitary fibrous tumour & endometrial stromal sarcoma (~40%), synovial sarcoma (~30%).<ref name=pmid15375433>{{cite journal |author=Ng TL, Gown AM, Barry TS, ''et al.'' |title=Nuclear beta-catenin in mesenchymal tumors |journal=Mod. Pathol. |volume=18 |issue=1 |pages=68–74 |year=2005 |month=January |pmid=15375433 |doi=10.1038/modpathol.3800272 |url=}}</ref> | ||
====A MFH DJH panel==== | |||
*Vimentin. | |||
*Alpha-1-antichymotrypsin. | |||
*CD34. | |||
*SMA. | |||
*S-100. | |||
*Keratin 5D3. | |||
*Keratin LP34. | |||
*EMA. | |||
*MSA. | |||
*Caldesmon. | |||
*MYF-4. | |||
*HMB45. | |||
*Mart-1. | |||
*Tyrosinase. | |||
==See also== | ==See also== |
edits